Skip to main content

Sirnaomics, NCI, InteRNA, VU University Medical Center

Sirnaomics Awarded NCI Grant to Develop Breast Cancer Therapy
Sirnaomics said this week that it has received a six-month Small Business Innovation Research grant from the National Cancer Institute to study its multi-targeted siRNA drug technology in the treatment of breast cancer.
According to the grant project’s abstract, Sirnaomics will use histidine-lysine polymer carriers with siRNA cocktails to target three specific genes — endothelial growth factor receptor, Raf-1 and mTOR. The company will then combine the regimen with Genentech’s cancer drug Avastin “to mimic a clinical regimen,” the abstract said.
The NCI grant is worth $228,000, and runs from Sept. 22 to the end of February.

InteRNA, VU University Medical Center to Collaborate on miRNA-Based Rx, Dx for Cancer
InteRNA Technologies, based in the Netherlands, said this week that it has signed a research agreement with the VU University Medical Center to develop microRNA-based diagnostics and therapeutics for cancer.
According to the company, it will use its lentiviral-based miRNA over-expression library in “multi-parametric, high-throughput screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in leukemia, colon, prostate, and head and neck cancer. In addition, diagnostic miRNA profiles will be developed through next-generation sequencing, in combination with InteRNA’s proprietary small RNA bioinformatics pipeline … on diverse patient sample sets” provided by the medical center.
Specific terms of the arrangement were not disclosed.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.